Recombinant Protein Technology 2016
Building on the successful launch of the ELRIG Advances in Recombinant Protein Technology conference in 2013, we are pleased to announce the 2nd in this series of meetings. The 2016 conference will focus on the latest advances in technologies for the design and production of recombinant proteins used as biotherapeutics and as reagents in drug discovery.
Understanding how to facilitate expression of novel and difficult proteins through protein and cell line engineering will be essential to support future drug discovery. It is an absolute prerequisite for drug discovery that recombinant proteins can be produced in sufficient amounts and are of appropriate quality. The repertoire of novel biologics has expanded beyond classical antibodies into production of therapeutic proteins and complex antibody formats that pose fresh challenges for existing expression systems.
During this two day conference, researchers from top academic and industrial laboratories will discuss the latest advances in recombinant protein technology. Themes will address our current understanding of molecular events that determine quality and productivity and the use of specific cell hosts for particular types of protein product. In particular, the conference will focus on the biology of existing host cells (with respect to their competency for protein expression) and how both host cell and desired proteins may be engineered to generate new systems for enhanced product expression. Presentations will cover developments in the following crucial areas in meeting future demands for recombinant proteins in drug discovery:
- Host Cell Factories
- Genome Editing
- Protein Engineering, Novel Proteins and Peptide Scaffolds
The two day conference will consist of oral presentations by plenary speakers and speakers selected from offered abstracts. In addition there will be a poster session with significant opportunities for networking.
This is a must-attend event to learn about the latest trends in Recombinant Protein Technology and new state-of-the-art technologies in drug discovery!
Associate Principal Scientist
Innovative Medicines, Discovery Sciences
Alan Dickson, PhD
Professor of Biotechnology
Director, Centre of Excellence in Biopharmaceuticals
Co-Director, BioProNET (a BBSRC NIBB, co-sponsored by EPSRC)
The University of Manchester
For Poster Presenters
Poster presentations at Recombinant Protein Technology are an excellent opportunity for delegates to network with their colleagues and communicate about their research. To be considered for a poster presentation, you must first submit an abstract for review by the meeting’s Scientific Program Committee.
For those wishing to participate, a subset of abstracts will also be considered for a short, poster taster session involving a 10 minute oral presentation within the main Symposia sessions. Decisions regarding acceptance of poster abstracts and/or selection for Poster Tasters will be communicated via e-mail in mid-May.
Deadlines for Submission:
Poster Taster Spot: 29th April 2016
General Poster Submission: 1st June 2016
All presenters must be registered as full-conference attendees in order to present at Recombinant Protein Technology.
Poster size should be no larger than A0 Portrait (W: 841mm x H: 1189mm).
ELRIG organizers will provide supplies to mount your posters, including velcro and/or pushpins.
We apologise that we are unable to accommodate posters which are any larger than A0 Portrait
Posters from Exhibiting Companies:
As an exhibitor, you have one poster spot included with your stand package.
Additional poster spots are £250 +VAT each.
Posters from Non-Exhibiting Companies:
Non-exhibiting vendor companies will be charged £250 +VAT for each poster submitted.
The speaker’s reception will take place on Tuesday 7th June 2016 with drinks at 7.30 and buffet from 8pm. The reception will take place at the AstraZeneca site:
Pepparedsleden 1, Mölndal